$MTSR News
Last published 12mo ago
- 12mo agoMTSRPFEPfizer Completes Acquisition of MetseraBusiness WireAcquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape Complements and transforms Pfizer's Internal Medicine portfolio Positions Pfizer to
- 1y agoMTSRPfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with PfizerPR NewswireMetsera, Inc. (NASDAQ: MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire...
- 1y agoMTSRMetsera Issues Statement in Response to Litigation RulingPR NewswireMetsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to a ruling in the litigation filed...
- 1y agoMTSRNOVO.B-DKPFENVO+1Healthy Returns: What to know about Pfizer and Novo Nordisk’s bidding war over obesity biotech MetseraCNBCPfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to extending tax credits.
- 1y agoMTSRNOVO.B-DKNVOPFE+1Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior�� to revised Pfizer offerCNBCThe clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in.
- 1y agoMTSRNOVOMetsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"PR NewswireMetsera, Inc. (NASDAQ: MTSR) ("Metsera") today announced that its Board of Directors had determined, after consultation with its outside counsel and...
- 1y agoMTSRNOVO.B-DKPFENVO+1Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotechCNBCThe suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the weight loss drug market.
- 1y agoMTSRMetsera Issues Statement in Response to LitigationPR NewswireMetsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to litigation filed against the Company by ...
- 1y agoMTSRMetsera Issues Statement in Response to LitigationPR NewswireMetsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to litigation filed against the Company by ...
- 1y agoMTSRPFEPfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera AcquisitionBusiness WirePfizer Inc. (NYSE:PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"),
- 1y agoMTSRNOVOMetsera Receives Unsolicited Proposal from Novo NordiskPR NewswireMetsera, Inc. (NASDAQ: MTSR) ("Metsera") today announced that its Board of Directors had determined, after consultation with its outside counsel and...
- 1y agoMTSRNVOPFEPfizer Addresses Proposal for MetseraBusiness WirePfizer Inc. (NYSE:PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE:NVO) to acquire Metsera, Inc. (NASDAQ:MTSR). It is an attempt by a company with a dominant market position to suppress
- 1y agoPFEMTSRNVOLLYHealthy Returns: Pfizer’s new obesity bet, Metsera, releases encouraging data on lead drugCNBCMetsera released data from mid-stage trials on its lead obesity drug candidate, while a high stakes Medicare open enrollment approaches.
- 1y agoMTSRMetsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3GlobeNewswirePlacebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateau Potential for best-in-class tolerability with minimal diarrhea signal, 13% nausea, and 11% vomiting
- 1y agoPFEMTSRLLYNVOPfizer boosts obesity drug prospects with $7.3 billion deal to buy MetseraCNBCMetsera, founded in 2022, brings a pipeline of both oral and injectable treatments with different targets that could boost Pfizer's odds of entering the market.
- 1y agoMTSRPFEPfizer to Acquire Metsera and its Next-Generation Obesity PortfolioBusiness WireProposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer's pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an initial enterprise
- 1y agoMTSRMetsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual MeetingGlobeNewswireNEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will present
- 1y agoMTSRMetsera to Present at Upcoming September Investor ConferencesGlobeNewswireNEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera" or the "Company"), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic
- 1y agoMTSRMetsera Reports Second Quarter 2025 Financial Results and Continued Portfolio ProgressGlobeNewswireMET-097i (fully biased once-monthly GLP-1 RA) VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered
- 1y agoMTSRMetsera to Present at Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewswireNEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera" or the "Company"), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic
- 1y agoMTSRMetsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233iGlobeNewswirePlacebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no
- 1y agoMTSRMetsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®GlobeNewswireFour presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional preclinical presentations on other differentiated portfolio assets,
- 1y agoMTSRMetsera Reports First Quarter 2025 Financial Results and Continued Portfolio ProgressGlobeNewswireMET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025 MET-233i, a monthly, ultra-long acting amylin analog,
- 1y agoMTSRMetsera to Present at Bank of America 2025 Global Healthcare ConferenceGlobeNewswireNEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera" or the "Company"), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic
- 1y agoMTSRMetsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio ProgressGlobeNewswireMET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and late 2025 on track
- 1y agoMTSRMetsera to Present at TD Cowen's 45th Annual Health Care ConferenceGlobeNewswireNEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera" or the "Company"), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic
- 1y agoMTSRMetsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional SharesGlobeNewswireNEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera"), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog
- 1y agoMTSRMetsera Announces Pricing of Initial Public OfferingGlobeNewswireNEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera"), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog